Empagliflozin, alone or in combination, in type 2 diabetes: Added benefit again not proven

(Institute for Quality and Efficiency in Health Care) The dossiers had the same weaknesses as in 2014. Data from the large study EMPA-REG-Outcome additionally submitted were unsuitable for an assessment of the added benefit in Germany.
Source: EurekAlert! - Medicine and Health - Category: Global & Universal Source Type: news